← Search & browse all drugs

ipidacrine

N06DA05

Forms & Strengths

Tablet: 20 mg
Solution for injection: 5 mg/mL, 15 mg/mL

Adult Dosing

Myasthenia gravis: 10-20 mg (1-2 mL of 1% solution) subcutaneously or intramuscularly 1-3 times daily, or 20 mg orally 1-3 times daily
Motor disorders/neuropathies: 10-20 mg IM/SC once or twice daily, or 20 mg orally 2-3 times daily
Maximum daily dose: 200 mg

Pediatric Dosing

Safety and efficacy not established in pediatric patients; use generally not recommended

Indications

Treatment of diseases of the peripheral nervous system (mononeuropathy, polyneuropathy, polyradiculoneuropathy)
Myasthenia and myasthenic syndrome of various etiologies
Bulbar paralysis and paresis
Recovery period after organic CNS lesions accompanied by motor disorders
Mild to moderate cognitive impairment of various origins (under specific regional approvals)

Mechanism of Action

Reversible inhibitor of acetylcholinesterase and butyrylcholinesterase in synapses
Blocks potassium channels in neuronal and muscle membranes
Enhances impulse transmission in the peripheral nervous system and neuromuscular junctions
Stimulates CNS function through moderately pronounced potentiation of synaptic transmission

Contraindications

Hypersensitivity to ipidacrine or excipients
Epilepsy
Vestibular disorders
Bradycardia and conduction blocks
Angina pectoris
Bronchial asthma
Mechanical obstruction of the intestine or urinary tract
History of vestibular disorders
Pregnancy and lactation

Adverse Reactions

Salivation
Bradycardia
Nausea and vomiting
Diarrhea
Abdominal pain
Bronchospasm
Sweating
Allergic reactions (rash, pruritus)

Drug Interactions

Enhances sedative effects when used concomitantly with other CNS depressants
Cholinomimetic effects are intensified when combined with other anticholinesterase agents
Beta-blockers may increase the risk of severe bradycardia
Ethanol increases the severity of adverse reactions

Curated Content: Needs Vetting Before Put to Clinical Use